Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Mark Gilbert MD
Closed to Accrual
Determine the maximum safe dose of single-agent treatment with ipilimumab, nivolumab and the combination when given with temozolomide during maintenance treatment for newly diagnosed glioblastoma.
Histopathologically proven diagnosis of glioblastoma or gliosarcoma prior to registration by pathology report. The tumor must be unifocal, confined to the supratentorial compartment and have undergone a gross total or near gross total resection.
Please noteThis is a limited-institution study with pre-selected sites.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.